Cadonilimab plus radiation for cervical cancer patients who cannot get standard chemo
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new immunotherapy drug called cadonilimab combined with radiation therapy for people with locally advanced cervical cancer who cannot receive the usual chemotherapy due to age, kidney problems, heart issues, allergies, or personal choice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have cervical squamous cell carcinoma or adenosquamous carcinoma that has spread locally but not to distant organs (FIGO stage IB3 to IVA), or you cannot have surgery and need radiation.
- You are in fairly good health (ECOG score 0-2) and expected to live at least 6 months.
- You have at least one reason why you cannot take cisplatin chemotherapy (like age 70+, kidney problems, heart issues, past allergy to platinum drugs, or you chose not to get chemo after full discussion).
- Your liver and kidney function are adequate (bilirubin, AST, ALT within limits).
- You have not had prior treatment with immune checkpoint inhibitors (like PD-1 or CTLA-4 blockers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding cadonilimab (an immune therapy) to standard radiation can improve treatment for locally advanced cervical cancer. It may help your immune system work better against the cancer while radiation shrinks it.
This trial tests adding a new immunotherapy drug (cadonilimab) to standard chemotherapy before surgery for locally advanced cervical cancer. The goal is to see if this combination helps shrink the tumor more effectively before surgery.
This trial tests a new immunotherapy drug, cadonilimab, combined with standard chemotherapy followed by chemoradiation for locally advanced cervical cancer. The goal is to see if this combination works better than current treatments.
This trial tests a combination of cadonilimab (an immune-boosting drug) plus chemotherapy for locally advanced cervical cancer that hasn't been treated before. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
This trial tests whether adding an immunotherapy drug called Cadonilimab (AK104) to standard chemoradiation can help people with locally advanced cervical cancer that has not spread to distant organs. The goal is to improve treatment outcomes for those who cannot have surgery.
This trial tests a new immunotherapy drug (cadonilimab) combined with standard chemoradiation for cervical cancer that has spread to a few other places in the body. It aims to see if this combination can help control the cancer better.
Hear when a new Locally Advanced Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.